Margetuximab对比曲妥珠单抗治疗经治ERBB2阳性晚期乳腺癌的III期随机临床试验
SOPHIA III期开放标签随机试验纳入536例经≥2线抗ERBB2治疗进展的ERBB2阳性晚期乳腺癌患者,比较Margetuximab+化疗与曲妥珠单抗+化疗。
要点
- Margetuximab组输液相关反应发生率更高(13.3% vs 3.4%),其余安全性相当。
核心结论
- 在经≥2线抗ERBB2治疗进展的ERBB2阳性晚期乳腺癌中,Margetuximab+化疗较曲妥珠单抗+化疗显著改善PFS,安全性可接受。
- 总生存期第二次中期分析未显示显著差异,最终OS分析预计2021年。
研究设计与样本
- SOPHIA III期随机开放标签试验,2015年8月26日至2018年10月10日入组536例患者,来自17个国家166个中心。
- 入组条件为既往≥2种抗ERBB2治疗进展且转移性疾病接受1-3线治疗,1:1随机分配至Margetuximab 15 mg/kg或曲妥珠单抗6 mg/kg(负荷8 mg/kg),每3周一个周期,化疗由研究者选择。
- 分层因素为转移部位(≤2 vs >2)、治疗线数(≤2 vs >2)和化疗选择。
主要发现
- 输液相关反应发生率Margetuximab组更高(35例[13.3%] vs 9例[3.4%]),多发生于第1周期,其余安全性相当。
关键数值与推荐
- Margetuximab剂量为15 mg/kg每3周,曲妥珠单抗为6 mg/kg每3周(负荷8 mg/kg)。
- 主要终点序贯为PFS(中心盲法)和OS,所有α分配先给PFS后给OS。
- 入组患者中除1例外均接受过帕妥珠单抗,489例(91.2%)接受过ado-trastuzumab emtansine。
临床怎么用
- 对于经多线抗ERBB2治疗进展的ERBB2阳性晚期乳腺癌,Margetuximab+化疗可作为改善PFS的选择之一。
- 使用Margetuximab时需注意输液相关反应,尤其在第1周期。
- OS获益尚未证实,需等待最终分析结果。
局限性
- OS数据来自第二次中期分析,尚未成熟。
- 开放标签设计可能影响研究者评估的终点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: ERRB2 (formerly HER2)-positive advanced breast cancer (ABC) remains typically incurable with optimal treatment undefined in later lines of therapy. The chimeric antibody margetuximab shares ERBB2 specificity with trastuzumab but incorporates an engineered Fc region to increase immune activation. OBJECTIVE: To compare the clinical efficacy of margetuximab vs trastuzumab, each with chemotherapy, in patients with pretreated ERBB2-positive ABC. DESIGN, SETTING, AND PARTICIPANTS: The SOPHIA phase 3 randomized open-label trial of margetuximab plus chemotherapy vs trastuzumab plus chemotherapy enrolled 536 patients from August 26, 2015, to October 10, 2018, at 166 sites in 17 countries. Eligible patients had disease progression on 2 or more prior anti-ERBB2 therapies and 1 to 3 lines of therapy for metastatic disease. Data were analyzed from February 2019 to October 2019. INTERVENTIONS: Investigators selected chemotherapy before 1:1 randomization to margetuximab, 15 mg/kg, or trastuzumab, 6 mg/kg (loading dose, 8 mg/kg), each in 3-week cycles. Stratification factors were metastatic sites (≤2, >2), lines of therapy (≤2, >2), and chemotherapy choice. MAIN OUTCOMES AND MEASURES: Sequential primary end points were progression-free survival (PFS) by central blinded analysis and overall survival (OS). All α was allocated to PFS, followed by OS. Secondary end points were investigator-assessed PFS and objective response rate by central blinded analysis. RESULTS: A total of 536 patients were randomized to receive margetuximab (n = 266) or trastuzumab (n = 270). The median age was 56 (27-86) years; 266 (100%) women were in the margetuximab group, while 267 (98.9%) women were in the trastuzumab group. Groups were balanced. All but 1 patient had received prior pertuzumab, and 489 (91.2%) had received prior ado-trastuzumab emtansine. Margetuximab improved primary PFS over trastuzumab with 24% relative risk reduction (hazard ratio [HR], 0.76; 95% CI, 0.59-0.98; P = .03; median, 5.8 [95% CI, 5.5-7.0] months vs 4.9 [95% CI, 4.2-5.6] months; October 10, 2018). After the second planned interim analysis of 270 deaths, median OS was 21.6 months with margetuximab vs 19.8 months with trastuzumab (HR, 0.89; 95% CI, 0.69-1.13; P = .33; September 10, 2019), and investigator-assessed PFS showed 29% relative risk reduction favoring margetuximab (HR, 0.71; 95% CI, 0.58-0.86; P < .001; median, 5.7 vs 4.4 months; September 10, 2019). Margetuximab improved objective response rate over trastuzumab: 22% vs 16% (P = .06; October 10, 2018), and 25% vs 14% (P < .001; September 10, 2019). Incidence of infusion-related reactions, mostly in cycle 1, was higher with margetuximab (35 [13.3%] vs 9 [3.4%]); otherwise, safety was comparable. CONCLUSIONS AND RELEVANCE: In this phase 3 randomized clinical trial, margetuximab plus chemotherapy had acceptable safety and a statistically significant improvement in PFS compared with trastuzumab plus chemotherapy in ERBB2-positive ABC after progression on 2 or more prior anti-ERBB2 therapies. Final OS analysis is expected in 2021. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02492711.
引用
- Rugo HS, Im SA, Cardoso F, et al. Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2021. PMID: 33480963. doi:10.1001/jamaoncol.2020.7932
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。